Trial Profile
A Randomized, Open-Label, Crossover Study to Demonstrate Bioequivalence Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Sep 2020
Price :
$35
*
At a glance
- Drugs Perampanel (Primary) ; Perampanel (Primary)
- Indications Epilepsy; Partial epilepsies; Seizures; Tonic-clonic epilepsy
- Focus Pharmacokinetics; Registrational
- Sponsors Eisai Co Ltd
- 01 Sep 2020 Primary endpoint (Area under the concentration-time curve from zero time to 168 hours (AUC[0-168h])) has been met, as per Results published in the International Journal of Clinical Pharmacology and Therapeutics
- 01 Sep 2020 Primary endpoint (Maximum observed concentration (Cmax)) has been met, as per Results published in the International Journal of Clinical Pharmacology and Therapeutics
- 01 Sep 2020 Results published in the International Journal of Clinical Pharmacology and Therapeutics